Alzheimer’s disease lymphocytes: potential for biomarkers?

Written by Urszula Wojda

The neurodegenerative disease described by Alois Alzheimer in 1906 is now recognized as a major aging-related dementia worldwide, affecting more than 35 million individuals. With the demographic shift toward aging societies, this number is expected to double every 20 years, to an estimated 135.5 million worldwide afflicted with the disease by 2050 [1]. The global costs related to diminished social functioning in AD patients are similar to the financial burdens of heart disease and cancer, placing Alzheimer’s disease (AD) among major public health concerns [2]. AD develops for tens of years in the preclinical phase before the onset of clinical...

To view this content, please register now for access

It's completely free